SHPH (Shuttle Pharmaceuticals Holdings) Short Interest


SHPH Shuttle Pharmaceuticals Holdings Inc SHPH
24 GF Score
Price $3.98
! 1 Warning Sign
View Full Analysis

What is Shuttle Pharmaceuticals Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

SHPH vs PRFX, CBIH, UPC: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shuttle Pharmaceuticals Holdings Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where Shuttle Pharmaceuticals Holdings's Short Interest falls into.


SHPH
24GF Score
Shuttle Pharmaceuticals Holdings Inc SHPH
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shuttle Pharmaceuticals Holdings Business Description

Address 401 Professional Drive, Suite 260, Gaithersburg, MD, USA, 20879
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
24GF Score

Get the complete analysis for SHPH

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.98
Price